Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Seagen Inc.
Kivu Bioscience Inc.
Eli Lilly and Company
Neonc Technologies, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
AstraZeneca
Tizona Therapeutics, Inc
Genentech, Inc.
Normunity AccelCo, Inc.
Eli Lilly and Company
MacroGenics
Theravectys S.A.
SystImmune Inc.
Daiichi Sankyo
Eli Lilly and Company
Adela, Inc
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
OncoNano Medicine, Inc.
Tanabe Pharma America, Inc.
Therorna
HiFiBiO Therapeutics
DualityBio Inc.
TScan Therapeutics, Inc.
TScan Therapeutics, Inc.
AstraZeneca
Massive Bio, Inc.
Incyte Corporation
Actym Therapeutics, Inc.
Chongqing Precision Biotech Co., Ltd
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC
Travera Inc
Nurix Therapeutics, Inc.
Incyte Corporation
Merck Sharp & Dohme LLC
Yuhan Corporation
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Klus Pharma Inc.